BiotechTube
Home/Pipeline/PD-1 Expression Inhibitor

PD-1 Expression Inhibitor

Immuno-oncology

PreclinicalActive

Key Facts

Indication
Immuno-oncology
Phase
Preclinical
Status
Active
Company
BCN Biosciences

About BCN Biosciences

BCN Biosciences is a preclinical biotech firm targeting high-need oncology segments, specifically KRAS-driven cancers (G12D, G12V) and immune checkpoint regulation via small molecules. The company differentiates itself through a novel mechanism aimed at restoring PTEN expression to combat KRAS mutations and a unique approach to modulating PD-1 in the tumor microenvironment. Founded in 2009, BCN has secured non-dilutive funding through SBIR grants and BARDA contracts, positioning its lead programs for potential partnership and advancement into clinical trials.

View full company profile

Therapeutic Areas

Oncology

Other Immuno-oncology Drugs

DrugCompanyPhase
PD-1/PD-L1 Inhibitor Binding Assay KitAurora BiolabsCommercial
CTLA-4/B7-1 Inhibitor Screening KitAurora BiolabsCommercial
OX40 & PD-1 AssayAurora BiolabsCommercial
HPK1 inhibitorAcelleraPre-clinical
SKP2-CKS1 PPI InhibitorIktosHit-to-Lead
CCR8 ADCIntegral MolecularPreclinical
KB16AKBioDiscovery
NeoSight Neoantigen DetectionReproCELLResearch/Clinical
EMUNKITUG (HFB200301)HiFiBiO TherapeuticsPhase 1
HFB200603HiFiBiO TherapeuticsPhase 1
Undisclosed Multispecific TherapeuticsModeX TherapeuticsPre-clinical
UndisclosedOnco3R TherapeuticsPreclinical